To back up a bit...here's some history, Opdivo style:
2014 - Opdivo (previously known as ONO4538, then MDX1106 [as it was called when I first started taking it], then BMS936558, then Nivolumab, and finally...Opdivo...dun, da, da dun!!!!) was approved for advanced melanoma patients after they had failed ipi and, if BRAF positive, BRAFi as well.
2015 - Opdivo was approved as a first line drug for unresectable or advanced melanoma, BUT....you had to be BRAF positive - though there was an abundance of data demonstrating that BRAF status made no difference!!!
2015 - also saw Opdivo approved for use in advanced renal cell carcinoma as well as non-squamous and non-small cell lung cancer, after platinum based chemo.
2016 - FINALLY, Opdivo was approved for use alone or with ipi, in advanced melanoma patients, no matter BRAF status.
Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib
That's all great news. The more help provided to cancer peeps the better!! NOW!!! How bout seeking approval for folks with Stage III melanoma, hmmmmmm??? I think we ratties have more than provided the needed data....with this research pretty much saying it all: Nivo better than ipi as adjuvant treatment for melanoma! Surprise, surprise, surprise!!!
Check out the link...or....here it is in a nutshell:
Call it by any name you like, BMS! Let's get THIS approval DONE!!! - c